Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto


1   0.064 (6.78%) 03-31 16:00
Open: 0.95 Pre. Close: 0.9365
High: 1 Low: 0.94
Volume: 170,550 Market Cap: 44(M)

Technical analysis

as of: 2023-03-31 4:16:56 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.46     One year: 1.76
Support: Support1: 0.84    Support2: 0.69
Resistance: Resistance1: 1.25    Resistance2: 1.5
Pivot: 1.11
Moving Average: MA(5): 1.01     MA(20): 1.17
MA(100): 1.01     MA(250): 0.94
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 23.3     %D(3): 26.8
RSI: RSI(14): 41.1
52-week: High: 1.92  Low: 0.56
Average Vol(K): 3-Month: 1,340 (K)  10-Days: 517 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AVRO ] has closed above bottom band by 27.4%. Bollinger Bands are 30.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.99 - 1 1 - 1
Low: 0.89 - 0.89 0.89 - 0.9
Close: 0.93 - 0.94 0.94 - 0.95

Company Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 30 Mar 2023
Dyadic Internationals Financial and Operational Results for 2021 ... - Best Stocks

Thu, 23 Mar 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... -

Thu, 23 Mar 2023
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial ... - Business Wire

Tue, 21 Mar 2023
Is Avrobio Inc (AVRO) a Good Buy in the Healthcare Sector? - InvestorsObserver

Fri, 03 Mar 2023
Is it Time to Dump Avrobio Inc (AVRO) Stock After it Is Up 3.62% in a Week? - InvestorsObserver

Fri, 03 Mar 2023
AVROBIO to Participate in Cowen's 43rd Annual Health Care ... - Business Wire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 44 (M)
Shares Float 32 (M)
% Held by Insiders 2.6 (%)
% Held by Institutions 53 (%)
Shares Short 424 (K)
Shares Short P.Month 125 (K)

Stock Financials

EPS -2.47
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.24
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -39.1
Return on Equity (ttm) -74.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.44
Qtrly Earnings Growth 0
Operating Cash Flow -99 (M)
Levered Free Cash Flow -61 (M)

Stock Valuations

PE Ratio -0.41
PEG Ratio 0
Price to Book value 0.44
Price to Sales 0
Price to Cash Flow -0.45

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.